NDA 219469 · Bayer Hlthcare
Lynkuet
Elinzanetant · Oral
NovelCDER novel approval, Oct 24, 2025: To treat moderate-to-severe vasomotor symptoms due to menopause
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Oct 24, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
22
4 Phase 3, 2 recruiting
FAERS reports
403
103 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 16, 2026.
LYNKUET is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. LYNKUET is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. ( 1 )
Mechanism: LYNKUET is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist. Inhibition of Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons can modulate neuronal activity in thermoregulation associated with hot flashes. Elinzanetant has higher affinity for human NK1 receptors (pKi values of 8.7 to 10.2) and NK3 receptors (pKi values of 8.0 to 8.8) than for human NK2 receptors (pKi values of approximately 6.0).
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- LYNKUET · ELINZANETANT 60MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elinzanetant" as an intervention, any sponsor and status, largest first.
BayerBayer (BAYRY)
NCT05030584 · 628 participants · Start Aug 27, 2021 · Primary completion Mar 29, 2023
Drug: Elinzanetant (BAY3427080); Placebo · For: Vasomotor Symptoms Associated With Menopause; Hot Flashes
Sites: Mobile, Alabama; Mesa, Arizona; Garden Grove, California · 86 sites in all
- A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerPivotal-lookingActive, not recruiting
BayerBayer (BAYRY)
NCT05587296 · 474 participants · Start Oct 14, 2022 · Primary completion Jan 29, 2024
Drug: Elinzanetant (BAY3427080); Placebo · For: Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Hot Flashes
Sites: Vienna, Austria; Salzburg, Austria; Wilrijk, Belgium · 102 sites in all
BayerBayer (BAYRY)
NCT05099159 · 400 participants · Start Oct 29, 2021 · Primary completion Jun 13, 2023
Drug: Elinzanetant (BAY3427080); Placebo · For: Vasomotor Symptoms Associated With Menopause; Hot Flashes
Sites: Birmingham, Alabama; Mobile, Alabama; Peoria, Arizona · 113 sites in all
BayerBayer (BAYRY)
NCT05042362 · 396 participants · Start Aug 27, 2021 · Primary completion Jul 25, 2023
Drug: Elinzanetant (BAY3427080); Placebo · For: Vasomotor Symptoms Associated With Menopause; Hot Flashes
Sites: Birmingham, Alabama; Mesa, Arizona; Scottsdale, Arizona · 99 sites in all
- A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor SymptomsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT03596762 · 199 participants · Start Nov 20, 2018 · Primary completion Nov 21, 2019
Drug: Elinzanetant (BAY3427080); Placebo · For: Menopause; Hot Flashes; Night Waking
Sites: Mesa, Arizona; San Diego, California; Aventura, Florida · 25 sites in all
- A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With MenopausePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT06112756 · 110 participants · Start Nov 8, 2023 · Primary completion Aug 22, 2024
Drug: Elinzanetant · For: Sleep Disturbances Associated With Menopause
Sites: Little Port Walter, Alaska; Scottsdale, Arizona; Encinitas, California · 40 sites in all
- Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study ParticipantsPivotal-lookingRecruiting
BayerBayer (BAYRY)
NCT07762287 · 100 participants (planned) · Start Jul 22, 2026 · Primary completion Jan 22, 2027
Drug: Elinzanetant (BAY 3427080) treatment A; Elinzanetant (BAY 3427080) treatment B · For: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women
Sites: Mount Royal, Canada
Massachusetts General HospitalAcademic, hospital or other
NCT07077395 · 80 participants (planned) · Start Mar 1, 2026 · Primary completion Jun 2029
Drug: elinzanetant - reference formulation; placebo · For: Menopause-related Hot Flashes
Sites: Boston, Massachusetts · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- somnolence70
- fatigue49
- dizziness39
- drug ineffective36
- incorrect dose administered33
- headache31
- product administered to patient of inappropriate age25
- hot flush24
- nausea24
- product prescribing issue18
- product use issue16
- vertigo16
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 5 |
| 2026 | 398 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.
Cardoso F, Parke S, Brennan DJ, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
Panay N, Joffe H, Maki PM, et al. · JAMA Intern Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.
Menegaz de Almeida A, Oliveira P, Lopes L, et al. · Obstet Gynecol 2025 · Systematic Review, Meta-Analysis
- Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Simon JA, Anderson RA, Ballantyne E, et al. · Menopause 2023 · Randomized Controlled Trial
- Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women.
Pawsey S, Mills EG, Ballantyne E, et al. · J Clin Endocrinol Metab 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
de Oliveira HM, Diaz CAV, Barbosa LM, et al. · Maturitas 2025 · Systematic Review, Meta-Analysis
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.